PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

NCT ID: NCT03850522

Last Updated: 2022-04-15

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-02-18
• Study Completion Date: 2021-03-10

Brief Summary

This study is evaluating a new vaccine against PD-L1 as a possible treatment for high-risk smoldering multiple myeloma.

Detailed Description

Smoldering multiple myeloma is an asymptomatic disorder with an annual risk of 10% of progression to the incurable cancer multiple myeloma. While many patients live for many years without progression, high risk patients have a median risk of progression of 29 months. No therapy has been approved for this indication. New treatments with limited adverse events are in high demand for this unmet medical need. An effective peptide vaccine would represent an ideal candidate, since vaccines generally have very low levels of side effects.

This study will explore if vaccination against the immune checkpoint molecule PD-L1 leads to responses in patients with high risk smoldering myeloma. PD-L1 is thought to play a role in the rate of progression from smoldering myeloma to symptomatic myeloma. Targeting this pathway with little risk of adverse events would potentially prevent or delay progression to symptomatic myeloma.

Conditions

Smoldering Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vaccination

Vaccination with PD-L1 peptide

Group Type: EXPERIMENTAL

PD-L1 peptide

Intervention Type: BIOLOGICAL

PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.

Interventions

PD-L1 peptide

PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.

Intervention Type: BIOLOGICAL

Other Intervention Names

IO103

Eligibility Criteria

Inclusion Criteria

• Patient has confirmed SMM according to a definition derived from the International Myeloma Working Group (IMWG) definition (International Working Group, 2003)

1. Serum M-component >30g/L and/or

2. Urine M-component ≥ 500mg/24 hours and/or

3. ≥10% clonal plasma cells in bone marrow

Exclusion Criteria

• High risk of progression to symptomatic multiple myeloma defined by the presence of ≥ 2 of the risk factors below:

• Bone marrow Plasma Cells (BMPCs) ≥ 20%
• M-component > 2g/dL
• FLC ratio > 20
• Age ≥18 years
• Performance status ≤ 2 (ECOG-scale)
• Expected survival > 3 months
• Sufficient liver function, i.e.

1. ALAT < 2.5 upper normal limit, i.e. ALAT <112 U/l

2. Bilirubin < 30 U/l

• Women agreement to use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 120 days after the last treatment.
• For men: agreement to use contraceptive measures and agreement to refrain from donating sperm.
• The accepted contraceptive methods are

• Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation. Oral, intravaginal or transdermal.
• Progestogen-only hormonal contraception associated with inhibition of ovulation. Oral, injectable, implantable.
• Intrauterine device (IUD)
• Intrauterine hormone-releasing system (IUS)
• Bilateral tubal occlusion
• Vasectomized partner
• Sexual abstinence

• Non-secretory myeloma
• Patients fulfilling CRAB criteria:

i. C: Hypercalcemia,

1. s-Ca-ion >1,40 mmol/L, attributable to myeloma ii. R: Renal failure

1. Estimated or measured creatinine clearance <40ml/min, attributable to myeloma

2. Increased s-creatinine, attributable to myeloma

3. Decrease in estimated or measured creatinine clearance <35% within a year, attributable to myeloma

4. Renal biopsy-verified renal changes attributable to myeloma iii. A: Anemia, Hgb < 6,3mmol/L (10g/dl), attributable to myeloma iv. B: Bone lesions on X-ray, CT or PET-CT

• Evidence of myeloma defining events i. Clonal bone marrow plasma cell percentage ≥ 60% ii. Ratio of involved/uninvolved serum free light chain ratio ≥ 100 iii. >1 focal lesions on MRI studies, if clinically indicated
• Plasma cell leukemia
• Signs of amyloidosis
• Other malignancies in the medical history excluding basal cell carcinoma of the skin, squamous cell carcinoma of the skin or in situ cervical cancer and patients cured for another malignant disease with no sign of relapse two years after ended treatment.
• Significant medical condition per investigators judgement e.g. severe Asthma/COPD, poorly regulated heart condition, insulin dependent diabetes mellitus.
• Acute or chronic viral infection e.g. HIV, hepatitis or tuberculosis
• Serious known allergies or earlier anaphylactic reactions.
• Known sensibility towards Montanide ISA-51
• Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency, autoimmune thyroiditis etc.
• Pregnant and breastfeeding women.
• Fertile women not using secure contraception with a failure rate less than < 1%
• Patients taking immune suppressive medications incl. corticosteroids and methotrexate at the time of enrollment
• Psychiatric disorders that per investigator judgment could influence compliance.
• Treatment with other experimental drugs
• Concurrent treatment with other anti-cancer drugs.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

IO Biotech

INDUSTRY

Sponsor Role: collaborator

Lene Meldgaard Knudsen

OTHER

Sponsor Role: lead

Responsible Party

Lene Meldgaard Knudsen

Head of Department, Department of Hematology

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Nicolai Jørgensen, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Hematology

Locations

Department of Hematology, Universityhospital Herlev and Gentofte

Herlev, , Denmark

Countries

Denmark

Other Identifiers

2018-003990-93

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

MY18H2

Identifier Type: -

Identifier Source: org_study_id